コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 uideline for the Management of Patients With Valvular Heart Disease".
2 ry disease, 20% atrial fibrillation, and 17% valvular heart disease).
3 and quality of echocardiographic studies for valvular heart disease.
4 ogenesis are important in the development of valvular heart disease.
5 ike to be the ultimate solution for treating valvular heart disease.
6 alve matrix architecture that are evident in valvular heart disease.
7 clerosis, myocardial infarction, stroke, and valvular heart disease.
8 tion, carcinoid tumors can cause right-sided valvular heart disease.
9 until it was reported to be associated with valvular heart disease.
10 weight loss may be associated with increased valvular heart disease.
11 receiving fenfluramine-phentermine developed valvular heart disease.
12 mmon type of inducible SMVT in patients with valvular heart disease.
13 ociated with improved concordance in grading valvular heart disease.
14 Users of diet medications are at risk for valvular heart disease.
15 ssed the issue of longitudinal assessment of valvular heart disease.
16 e-phentermine therapy may be associated with valvular heart disease.
17 ffects, including pulmonary hypertension and valvular heart disease.
18 ccredited laboratories for the evaluation of valvular heart disease.
19 reasing recognition of nonrheumatic forms of valvular heart disease.
20 s (289 male, 67+/-10 years) with ischemic or valvular heart disease.
21 Aortic stenosis is the most frequent valvular heart disease.
22 nowledge for the management of patients with valvular heart disease.
23 ion, and research in the field of structural valvular heart disease.
24 cardiomyopathy, ischemic heart disease, and valvular heart disease.
25 is that selective 5-HT2C agonism would avoid valvular heart disease.
26 heter therapies are being developed to treat valvular heart disease.
27 Aortic stenosis is the most common form of valvular heart disease.
28 ost challenging encountered in patients with valvular heart disease.
29 re more likely to have history of stroke and valvular heart disease.
30 guidance, and post-procedural assessment of valvular heart disease.
31 ntional surgery in the treatment of acquired valvular heart disease.
32 ic dysfunction, diastolic abnormalities, and valvular heart disease.
33 l for identifying compounds likely to induce valvular heart disease.
34 idelines for the Management of Patients With Valvular Heart Disease.
35 echanism for development of the drug-induced valvular heart disease.
36 ercutaneous approaches for the correction of valvular heart disease.
37 gold standard for treatment of patients with valvular heart disease.
38 en a concordant decline in the prevalence of valvular heart disease.
39 heir development of effective treatments for valvular heart disease.
40 ive endocarditis in patients with underlying valvular heart disease.
41 pathway may play a role in the mechanism for valvular heart disease.
42 ge, body mass index, smoking, and history of valvular heart disease.
43 important treatment option for patients with valvular heart diseases.
44 aortic stenosis is the most prevalent of all valvular heart diseases.
45 art disease, 1.07 (95% CI, 0.89 to 1.30) for valvular heart disease, 1.07 (95% CI, 0.96 to 1.19) for
46 on for ischemic heart disease (9.9% v 9.7%), valvular heart disease (2.9% v 2.8%), conduction abnorma
47 mic heart disease (410-414, 36.0, and 36.1), valvular heart disease (394-397, 424, 35), congestive he
48 4%), pulmonary vascular disease (1.2%-7.1%), valvular heart disease (5.0%-9.8%), and renal failure (7
49 were being evaluated for stable angina (53), valvular heart disease (8), atypical chest pain (12), or
50 al advances is providing unique solutions to valvular heart disease also requiring revascularization,
51 itial association between the development of valvular heart disease and drugs stems from observations
52 our understanding of the pathophysiology of valvular heart disease and in the surgical techniques fo
53 y common and unexpected finding in end-stage valvular heart disease and may be associated with repair
54 y multivariate analyses, in subjects free of valvular heart disease and preexisting cardiovascular di
56 emonstrates that the Lewis rat is a model of valvular heart disease and that streptococcal M protein
57 une responses against cardiac myosin lead to valvular heart disease and the infiltration of the heart
58 ase, diabetes mellitus, atrial fibrillation, valvular heart disease, and antihypertensive medication
61 ting factors, such as renal artery stenosis, valvular heart disease, and ischemia, should be strongly
62 Mitral regurgitation (MR) is the most common valvular heart disease, and mitral valve surgery is the
63 as chest pain, congestive heart failure, and valvular heart disease, and preoperative risk assessment
64 ardial infarction, congestive heart failure, valvular heart disease, and stroke or transient ischemic
65 erial revascularization, rheumatic and other valvular heart disease, and symptomatic bradyarrhythmia;
66 ders & Lipids, Rhythm Disorders, Statistics, Valvular Heart Disease, and Vascular Medicine (1-63).
67 tabolic & Lipid Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine (1-84).
68 urodegenerative Disorders, Rhythm Disorders, Valvular Heart Disease, and Vascular Medicine (1-86).
72 l similarities between coronary and calcific valvular heart disease (aortic stenosis [AS] and mitral
73 and comorbidities such as renal failure and valvular heart disease are independent predictors for AF
75 holds immense potential for the treatment of valvular heart disease as adjuncts to surgical intervent
76 rticle reviews unique advantages emerging in valvular heart disease as the technology of invasive car
77 es have much promise as biomarkers in common valvular heart disease, but the impact of their measurem
78 cardiomyopathy, hypertensive heart disease, valvular heart disease, cerebrovascular disease or nonca
79 e models, the use of diuretics, a history of valvular heart disease, coronary disease, advancing age,
81 olesterol; history of myocardial infarction, valvular heart disease, diabetes, lung disease, and use
82 m surrounding the diagnosis and treatment of valvular heart disease, driven in part by emerging percu
84 American College of Cardiology guidelines on valvular heart disease generated considerable controvers
87 lions of individuals with coronary artery or valvular heart disease have been given a new chance at l
88 k and benefit of mechanical interventions in valvular heart disease have been primarily described amo
89 2), atrial fibrillation HR 1.54 (1.36-1.73), valvular heart disease HR 1.23 (1.05-1.44), thromboembol
92 fenfluramine (phen-fen) on the prevalence of valvular heart disease in 226 obese subjects enrolled in
94 es were dilated cardiomyopathy in 119 (53%), valvular heart disease in 34 (15%), arrhythmogenic right
95 ary heart disease in 278 participants (52%), valvular heart disease in 42 (8%), hypertension in 140 (
97 on, history of congestive heart failure, and valvular heart disease in Cox proportional hazards model
100 Because streptococcal M proteins produced valvular heart disease in Lewis rats and have been linke
101 ent, progression and regression of carcinoid valvular heart disease in patients with carcinoid syndro
102 the pulmonic position in 2000, treatment for valvular heart disease in the outflow position has becom
103 contributing to altered profiles of acquired valvular heart disease in the past few decades include a
105 e (DAVD) has become the most common cause of valvular heart disease in the Western world, causing sig
106 se is increasing in importance as a cause of valvular heart disease in urban centers in the United St
107 c stenosis is perhaps the most common of all valvular heart diseases in the developed nations of the
118 th observed in patients with hypertension or valvular heart diseases is called maladaptive or patholo
119 hypertension, sex, left atrial enlargement, valvular heart disease, left ventricular ejection fracti
120 rol ratio, prevalent coronary heart disease, valvular heart disease, left ventricular hypertrophy, an
122 sex) and clinical (diabetes, smoking status, valvular heart disease, medications, indications for cat
123 stress in the aortic valve, with functional valvular heart disease, mimicking the clinical syndrome.
125 er, decreased ejection fraction, presence of valvular heart disease or the use of concomitant medicat
126 tory of coronary artery disease, MI, CHF, or valvular heart disease (OR 1.6 [95% CI 0.9-2.6]), revisi
127 or impact on the management of patients with valvular heart disease over the next several years.
130 ered as the mechanism of VT in patients with valvular heart disease, particularly if the arrhythmia o
131 ts (N=114, 49%) compared with (ischemic and) valvular heart disease patients (N=26, 17%; P<0.001).
133 ry artery disease, congestive heart failure, valvular heart disease, pericardial disease, conduction
135 ask Force on the management of patients with valvular heart disease proscribe the use of bioprostheti
136 stive heart failure, ischemic heart disease, valvular heart disease, pulmonary hypertension, and cong
137 used on hemodynamic measurements to evaluate valvular heart disease, pulmonary hypertension, cardiomy
138 METHODS AND We enrolled 335 consecutive valvular heart disease subjects who underwent echocardio
140 n investigated for its role in production of valvular heart disease, the most serious sequelae of gro
141 gh surgery was the mainstay of treatment for valvular heart disease, transcatheter valve therapies ha
143 tudy was to evaluate the association between valvular heart disease (VHD) and maternal and fetal outc
145 The occurrence of fenfluramine-associated valvular heart disease (VHD) has raised concerns that ot
147 with atrial fibrillation (AF) and coexisting valvular heart disease (VHD) is of substantial interest.
148 art valves, significant mitral stenosis, and valvular heart disease (VHD) requiring intervention were
150 or in mediating the heart valve fibroplasia [valvular heart disease (VHD)] and primary pulmonary hype
153 essants fenfluramine and dexfenfluramine and valvular heart disease was first described in patients f
157 diabetes, left ventricular hypertrophy, and valvular heart disease were predictive of increased risk
158 gy/American Heart Association guidelines for valvular heart disease were released to help guide the c
159 , valve tissues from rheumatic patients with valvular heart disease who required valve replacement we
160 fraction < or =35%) and without significant valvular heart disease who underwent PET/FDG study at th
161 ed age, with chronic kidney disease, or with valvular heart disease will be discussed as well as the
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。